U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H22ClF2NO4
Molecular Weight 437.864
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IRX-5183

SMILES

CC1(C)CCC(C)(C)C2=C1C=C(C(=O)NC3=CC(F)=C(C(O)=O)C(F)=C3)C(O)=C2Cl

InChI

InChIKey=PNAWUIKCVQSLFG-UHFFFAOYSA-N
InChI=1S/C22H22ClF2NO4/c1-21(2)5-6-22(3,4)16-12(21)9-11(18(27)17(16)23)19(28)26-10-7-13(24)15(20(29)30)14(25)8-10/h7-9,27H,5-6H2,1-4H3,(H,26,28)(H,29,30)

HIDE SMILES / InChI

Approval Year

Name Type Language
IRX-5183
Common Name English
NRX-195183
Code English
AGN-195183
Code English
AGN 195183
Code English
VTP-195183
Code English
BENZOIC ACID, 4-(((4-CHLORO-5,6,7,8-TETRAHYDRO-3-HYDROXY-5,5,8,8-TETRAMETHYL-2-NAPHTHALENYL)CARBONYL)AMINO)-2,6-DIFLUORO-
Systematic Name English
VTP-5183
Code English
NRX195183
Code English
Code System Code Type Description
CAS
367273-07-2
Created by admin on Fri Dec 15 15:30:53 GMT 2023 , Edited by admin on Fri Dec 15 15:30:53 GMT 2023
PRIMARY
DRUG BANK
DB05653
Created by admin on Fri Dec 15 15:30:53 GMT 2023 , Edited by admin on Fri Dec 15 15:30:53 GMT 2023
PRIMARY
PUBCHEM
9867758
Created by admin on Fri Dec 15 15:30:53 GMT 2023 , Edited by admin on Fri Dec 15 15:30:53 GMT 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
IRX-5183
Created by admin on Fri Dec 15 15:30:53 GMT 2023 , Edited by admin on Fri Dec 15 15:30:53 GMT 2023
PRIMARY AGN 195183 is a potent and selective agonist of RAR.ALPHA.(Kd=3 nM) with improved binding selectivity relative to AGN 193836no activity on RAR.BETA./.GAMMA..IC50 value: 3 nM (Kd)200 nM (EC80, RAR Trans.)Target: RAR.ALPHA. agonistCompound 4(AGN-195183) inhibited the growth of breast cancer cell lines, and was inactive in an in vivo model of topical irritation.Compound 4 and ATRA inhibit growth of the human breast cancer cell lines, T-47D and SK-BR-3, compound 4 does not cause the topical irritation induced by the RARa-selective retinoid, Am-580. Compound 4 (AGN 195183) is currently in Phase I/IIA clinical trials in cancer patients.
ChEMBL
CHEMBL107430
Created by admin on Fri Dec 15 15:30:53 GMT 2023 , Edited by admin on Fri Dec 15 15:30:53 GMT 2023
PRIMARY
CAS
1275609-69-2
Created by admin on Fri Dec 15 15:30:53 GMT 2023 , Edited by admin on Fri Dec 15 15:30:53 GMT 2023
NO STRUCTURE GIVEN
FDA UNII
RC87L028HU
Created by admin on Fri Dec 15 15:30:53 GMT 2023 , Edited by admin on Fri Dec 15 15:30:53 GMT 2023
PRIMARY
NCI_THESAURUS
C77899
Created by admin on Fri Dec 15 15:30:53 GMT 2023 , Edited by admin on Fri Dec 15 15:30:53 GMT 2023
PRIMARY